After Takeda lost exclusivity of Vyvanse last year, the FDA approved generic versions of Vyvanse from 11 drugmakers, including U.S.-based drugmakers Mallinckrodt and Viatris, UK-based Hikma ...

Worldcategory Dechra, Hikma, M&S and Diploma set to join FTSE 100 August 23, 2023 Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider ...

THURSDAY, Sept. 5, 2024 (HealthDay News) -- The maker of the ADHD drug Vyvanse has been given approval by the U.S. Drug Enforcement Administration to make more of the medication as a shortage of ...

Following a request from the U.S. Food and Drug Administration in July, the DEA said Thursday that Takeda Pharmaceuticals may now increase its production limit by 24%.

Hikma Pharmaceuticals PLC HIK shares inched up 0.82% to £19.77 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with the FTSE 100 Index UKX falling 0.35% ...

US FDA approved generic versions of Vyvanse from 11 drugmakers, including U.S.-based drugmakers Mallinckrodt and Viatris, UK-based Hikma Pharmaceuticals, and Indian drugmaker Sun Pharmaceutical ...

UK-based Hikma Pharmaceuticals, and Indian drugmaker Sun Pharmaceutical Industries, last year after Takeda lost exclusivity over the drug. Bloomberg News first reported about the increased limits ...

Hikma is offering clindamycin in 5% dextrose injection, in 300mg/50ml, 600mg/50ml and 900mg/50ml doses. The product is available in a vial. Clindamycin in 5% dextrose injection is indicated for ...